Clinical Trials in Barranquilla, Atlántico
48 recruiting
Showing 1–20 of 44 trials
Recruiting
Phase 2
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
Radiographic Axial Spondyloarthritis
Merck Sharp & Dohme LLC315 enrolled100 locationsNCT07133633
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled261 locationsNCT06841354
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Merck Sharp & Dohme LLC1,023 enrolled130 locationsNCT07216703
Recruiting
Phase 2
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
Psoriatic Arthritis
Merck Sharp & Dohme LLC140 enrolled43 locationsNCT07486960
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled212 locationsNCT06422143
Recruiting
Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Coronavirus Disease (COVID-19)
Merck Sharp & Dohme LLC3,082 enrolled224 locationsNCT06667700
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled782 locationsNCT03486873
Recruiting
Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled240 locationsNCT06935357
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled295 locationsNCT06926868
Recruiting
Phase 2
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Primary Sjögren's Syndrome
Immunovant Sciences GmbH180 enrolled121 locationsNCT06979531
Recruiting
Phase 1
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
Rheumatoid ArthritisSystemic Lupus Erythematosus
Merck Sharp & Dohme LLC21 enrolled15 locationsNCT07363590
Recruiting
Phase 3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,390 enrolled81 locationsNCT07044297
Recruiting
Phase 4
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Sickle Cell Disease
Novartis Pharmaceuticals130 enrolled31 locationsNCT04657822
Recruiting
Phase 1Phase 2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Diffuse Large B Cell LymphomaEwing SarcomaNeuroblastoma+2 more
Merck Sharp & Dohme LLC90 enrolled70 locationsNCT06395103
Recruiting
Phase 3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb750 enrolled273 locationsNCT07361510
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Secondary-progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals1,275 enrolled208 locationsNCT07225504
Recruiting
Phase 2
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
Chagas Disease
Novartis Pharmaceuticals130 enrolled20 locationsNCT06632600
Recruiting
Phase 2Phase 3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Heart FailureLeft Ventricular Systolic Dysfunction
Merck Sharp & Dohme LLC342 enrolled106 locationsNCT05714085
Recruiting
Phase 2
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Arthritis, Rheumatoid
Merck Sharp & Dohme LLC182 enrolled62 locationsNCT07176390
Recruiting
Phase 2
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Lupus Nephritis
Novartis Pharmaceuticals240 enrolled103 locationsNCT05268289